Efficacy of Palivizumab Prophylaxis Among Infants With Congenital Heart Disease: A Case Control Study

Ozyurt A., NARİN N., BAYKAN A., Argun M., PAMUKÇU Ö., ZARARSIZ G., ...More

PEDIATRIC PULMONOLOGY, vol.50, no.10, pp.1025-1032, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 50 Issue: 10
  • Publication Date: 2015
  • Doi Number: 10.1002/ppul.23102
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1025-1032
  • Keywords: clinical trials, congenital heart disease, palivizumab prophylaxis, lower respiratory tract infections, RSV, hospitalization, risk factors, RESPIRATORY SYNCYTIAL VIRUS, HIGH-RISK CHILDREN, COST-EFFECTIVENESS, YOUNG-CHILDREN, INFECTION, PREVENTION, IMPACT
  • Erciyes University Affiliated: Yes


Background: Palivizumab prophylaxis for RSV has been consistently reported to reduce the risk of hospital admissions related to RSV infection in children with symptomatic cardiac disease. This study was designed to investigate the efficacy of palivizumab prophylaxis among infants with congenital heart disease (CHD) in Turkey.